PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today the pricing terms of the previously announced cash tender offers (the "Any and All Tender Offers" and each, an "Any and All Tender Offer") of Viatris and its subsidiary Mylan Inc. ("Mylan" and, together with Viatris, the "Offerors" and each, an "Offeror") for any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris (the "Viatris Notes") and any and all of the outstanding 2. ...

PITTSBURGH, Sept. 4, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS, "Viatris" or the "Company") announced today that it and its subsidiaries, Mylan Inc. ("Mylan") and Utah Acquisition Sub Inc. ("Utah Acquisition" and, together with Viatris and Mylan, the "Offerors" and each, an "Offeror"), have commenced tender offers (each individually, with respect to a series of notes, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for cash (1) any and all of the outstanding 1.650% Senior Notes du ...

Study Results - Cenerimod demonstrated safety and tolerability in Japanese patients with moderate to severe systemic lupus erythematosus (SLE), with both 2 mg and 4 mg doses showing clinically meaningful improvements in disease activity as measured by mSLEDAI-2K [1][2][3] - The 4 mg dose of cenerimod showed a higher improvement in disease activity compared to the 2 mg dose, with effects persisting long after treatment discontinuation [3] - The results are consistent with global Phase 2 CARE study findings, reinforcing the potential of cenerimod as a treatment for SLE [3][9] Study Design - The ACT-333441 study was a randomized, double-blind, parallel-group, multicenter Phase 2 trial conducted in Japan, involving 17 patients with moderate to severe SLE [2] - Patients were randomized equally to receive either 2 mg or 4 mg of cenerimod once daily, with primary endpoints focusing on safety and tolerability, and secondary endpoints measuring changes in lymphocyte count and efficacy using mSLEDAI-2K [2] About SLE and Cenerimod - Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by overactive T and B lymphocytes, leading to inflammation and organ damage [5] - Cenerimod is an investigational oral S1P1 receptor modulator, offering a novel approach to treating SLE, a disease with limited treatment options [6] Regulatory and Development Status - Cenerimod has received Fast-Track designation from the U.S. FDA, aimed at accelerating development for serious conditions with unmet medical needs [8] - The OPUS program, initiated in December 2022, includes two Phase 3 studies to evaluate cenerimod's efficacy, safety, and tolerability in adult patients with moderate-to-severe SLE [7] Company Overview - Viatris Inc is a global healthcare company focused on providing access to high-quality medicines, supplying approximately 1 billion patients annually [10] - The company combines generics and brands to address global healthcare needs, with a mission to empower people to live healthier lives [10]

Viatris (VTRS) reported $3.8 billion in revenue for the quarter ended June 2024, representing a year-over-year decline of 3.1%. EPS of $0.69 for the same period compares to $0.75 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $3.82 billion, representing a surprise of -0.49%. The company delivered an EPS surprise of +1.47%, with the consensus EPS estimate being $0.68. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street exp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________to___________ Commission file number 001-39695 VIATRIS INC. (Exact name of registrant as specified in its charter) Delaware 83-4364296 (State or other jurisd ...

On Thursday, Viatris Inc. VTRS reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis. Brands net sales reached $2.36 billion, reflecting strong growth in Greater China and the expansion of the company's portfolio in Emerging Markets and JANZ, partially offset by unfavorable channel dynamics in North America and the impact of government price regulations in Japan and Australia. Related: Novartis And Viatris Sue ...

Investors are applauding the healthcare company's improving growth story. Shares of Viatris (VTRS 5.90%) were jumping 6% higher as of 11:18 a.m. ET on Thursday after rising as much as 12.4% earlier in the day. The solid gain came after the global healthcare company announced its secondquarter results before the market opened. Viatris reported Q2 revenue of nearly $3.8 billion. Although this reflected a 3% year-over-year decline, it met Wall Street expectations. The company recorded a Q2 net loss of $326 mil ...

Viatris Inc. (NASDAQ:VTRS) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott Smith - Chief Executive Officer Corinne Le Goff - Chief Commercial Officer Philippe Martin - Chief R&D Officer Doretta Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Ekaterina Knyazkova - JPMorgan David Amsellem - Piper Sandler Umer Raffat - Evercore ISI Balaji Prasad - Barclays Bhavin Patel - Bank of America Operator G ...

Viatris Inc. (VTRS) delivered second-quarter 2024 adjusted earnings of 69 cents per share, which beat the Zacks Consensus Estimate by a penny. The company recorded adjusted earnings of 75 cents per share in the year-ago quarter. Total revenues came in at $3.79 billion, down 3.1% year over year on a divestiture-adjusted operational basis. Revenues include product sales and other revenues. The top line missed the Zacks Consensus Estimate of $3.81 million. The stock is trading up in response to the second-quar ...

Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 1.47%. A quarter ago, it was expected that this generic drugmaker would post earnings of $0.68 per share when it actually produced earnings of $0.67, delivering a surprise of -1.47%. Over the last four quarters, the compan ...